Itraconazole Should Generally Be Avoided During Pregnancy, Especially in the First Trimester
Itraconazole should not be routinely administered during pregnancy unless the potential benefit clearly outweighs the risk, and alternative safer antifungals cannot be used. The FDA drug label explicitly states that itraconazole caused dose-related embryotoxicity and teratogenicity in animal studies, and cases of congenital abnormalities have been reported in postmarketing surveillance 1.
Key Evidence from FDA Labeling
The FDA drug label provides critical safety information:
- Animal studies demonstrated teratogenicity: Major skeletal defects in rats and encephaloceles/macroglossia in mice at doses equivalent to human therapeutic levels 1
- Crosses the placenta: Confirmed in rat models 1
- Postmarketing reports: Cases of congenital abnormalities have been documented 1
- No adequate human studies: "There are no studies in pregnant women" 1
- Official recommendation: "Should be used in pregnancy only if the benefit outweighs the potential risk" 1
- Contraception requirement: Highly effective contraception should be continued throughout therapy and for 2 months following treatment 1
Human Observational Data Shows Mixed Results
While two prospective cohort studies provide some reassurance regarding major malformations, they reveal concerning signals:
Regarding major malformations: Studies found no significant increase in major congenital anomalies (1.8-3.2% in exposed vs 2.1-4.8% in controls) 2, 3. However, these sample sizes were relatively small (156-163 live births in exposed groups).
Critical concern - spontaneous abortion: Both studies demonstrated significantly higher rates of spontaneous abortion in itraconazole-exposed pregnancies 2, 3. One study noted increased rates of both spontaneous abortion (11.2% vs 4.8%) and therapeutic abortion (9.2% vs 3.4%) compared to controls 2.
Clinical Decision Algorithm
When Itraconazole Might Be Considered (Second/Third Trimester Only):
According to coccidioidomycosis management guidelines, azole antifungals including itraconazole may be used in the second and third trimesters for serious fungal infections when:
- The infection poses significant maternal morbidity/mortality risk
- Amphotericin B-based regimens are not feasible or have failed 4
First Trimester - Avoid:
The first trimester is the highest risk period. For serious fungal infections during the first trimester, amphotericin-based regimens should be used instead 4. The guideline explicitly recommends avoiding azoles if possible during this critical organogenesis period 4.
For Non-Life-Threatening Infections:
- Superficial fungal infections (vaginal candidiasis, dermatophytosis): Use topical antifungals throughout pregnancy
- Defer treatment when possible until after delivery
- Consider alternative systemic agents with better safety profiles if treatment cannot be delayed
Important Caveats
- Breastfeeding: Women should not breastfeed while receiving itraconazole, as it enters breast milk and may accumulate over time 4
- Dose matters: The observational study showing increased spontaneous abortion risk involved vaginal candidiasis treatment (likely lower doses), not high-dose therapy 4
- Quality of evidence: The human safety data comes from relatively small observational studies, not randomized trials, limiting definitive conclusions
Bottom Line
The combination of animal teratogenicity data, FDA warnings, postmarketing reports of congenital abnormalities, and increased spontaneous abortion rates in human studies makes itraconazole inappropriate for routine use during pregnancy. Reserve it only for life-threatening maternal fungal infections in the second/third trimester when safer alternatives are inadequate, and avoid completely in the first trimester.